SCHEMBL6880385

SCHEMBL6880385

O=C(O)c1ccc(-n2nc3ccc4ccccc4c3n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.61
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
HSD17B10 Q99714 1/20 0.48
PLA2G10 O15496 1/20 0.46
MAPK1 P28482 1/20 0.45
PARP1 P09874 1/20 0.45
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HTT P42858 1/20 0.43
GFER P55789 1/20 0.41
EGLN1 Q9GZT9 1/20 0.40
ATM Q13315 1/20 0.40
SLC2A1 P11166 1/20 0.40
TSHR P16473 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10784846 0.93 ALOX5 (0.54) ALOX5ALDH1A1HPGDHSD17B10GFER
SCHEMBL10895222 0.93 ALOX5 (0.54) ALOX5ALDH1A1HPGDHSD17B10GFER
SCHEMBL23517134 0.87 ALOX5 (0.77) ALOX5ALDH1A1HPGDHSD17B10PARP1
SCHEMBL22539825 0.85 ALOX5 (0.57) ALOX5ALDH1A1HPGDHSD17B10PLA2G10
SCHEMBL10330358 0.85 ALOX5 (0.70) ALOX5ALDH1A1HPGDHSD17B10PARP1
SCHEMBL14281072 0.82 ALOX5 (0.71) ALOX5ALDH1A1HPGDHSD17B10PARP1
SCHEMBL13817411 0.81 ALOX5 (0.56) ALOX5ALDH1A1HPGDMAPK1NPSR1
SCHEMBL12706192 0.80 ALOX5 (0.68) ALOX5ALDH1A1HPGDHSD17B10PARP1
SCHEMBL10968802 0.80 ALOX5 (0.72) ALOX5ALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL11911474 0.80 ALOX5 (0.68) ALOX5ALDH1A1HPGDHSD17B10PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1520450-B1 ELECTROLUMINESCENT DEVICE UDC IRELAND LTD (IE) 2017-08-02 EP disclosed
US-7541096-B2 Blue emitting, durable, organoelectrouminescent layers containing 2H-benzotriazole compounds; full color display panels; light emission efficiency and brightness CIBA SPECIALTY CHEMICALS CORPORATION (US) 2009-06-02 US disclosed
US-6835329-B2 Photostability; hindered amine light stabilizers CIBA SPECIALTY CHEMICALS CORPORATION 2004-12-28 US disclosed
US-20040049052-A1 Benzophenone uv-absorbers with heterocyclic substituents CIBA SPECIALTY CHEMICALS CORP. 2004-03-11 US disclosed
US-20040013619-A1 Heteroaryl substituted hydroxyphenyltriazine uv-absorbers CIBA SPECIALTY CHEMICALS CORP. 2004-01-22 US disclosed
EP-1351943-A1 BENZOPHENONE UV-ABSORBERS WITH HETEROCYCLIC SUBSTITUENTS Ciba SC Holding AG (CH) 2003-10-15 EP disclosed
EP-1322640-A1 HETEROARYL SUBSTITUTED HYDROXYPHENYLTRIAZINE UV-ABSORBERS Ciba SC Holding AG (CH) 2003-07-02 EP disclosed
WO-2002048118-A1 BENZOPHENONE UV-ABSORBERS WITH HETEROCYCLIC SUBSTITUENTS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-06-20 WO disclosed
WO-2002028854-A1 HETEROARYL SUBSTITUTED HYDROXYPHENYLTRIAZINE UV-ABSORBERS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040049052-A1 Benzophenone uv-absorbers with heterocyclic substituents TRPC1, C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ALOX5 2430/4885ALDH1A1 1405/4885HPGD 3629/4885
US-20040013619-A1 Heteroaryl substituted hydroxyphenyltriazine uv-absorbers CBR1, CYP4Z1, CYP1A1 ALOX5 640/4885ALDH1A1 276/4885HPGD 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.